



Holding(s) in Company

February 22, 2022

RNS Number : 4691C

MaxCyte, Inc.

22 February 2022

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

US57777K1060

Issuer Name

MAXCYTE, INC.

UK or Non-UK Issuer

Non-UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Vitruvian Partners LLP

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name	City of registered office	Country of registered office
Life Tech S.à r.l.	Luxembourg	Luxembourg

5. Date on which the threshold was crossed or reached

17-Feb-2022

6. Date on which Issuer notified

21-Feb-2022

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	4.010000	0.000000	4.010000	4053531
Position of previous notification (if applicable)	3.110000	0.000000	3.110000	

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares I SIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
US57777K1060	4053531	0	4.010000	0.000000
Sub Total 8.A	4053531		4.010000%	

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1				

8B2. Financial Instruments with similar economic effect according to

(DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total					
8.B2					

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

- The Vitruvian Investment Partnership III is managed by Vitruvian Partners LLP and is deemed to be the ultimate beneficial owner of Life Tech S.à r.l.
- The voting rights attached to shares disclosed herein - 4,053,531, equivalent to 4.01% of issuer's voting rights - are comprised by 2,430,000 LSE (AIM) listed shares (LSE SEDOL: BYVJZ42) and by 1,623,531 US NASDAQ listed shares (NASDAQ: SEDOL BKM0F66).

12. Date of Completion

21-Feb-2022

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

HOLFLFEEFFIFFIF